Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase ii clinical trial

HIGHLIGHTS

• who: Tito R. Mendoza from the DepartmentThe University have published the research: Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial, in the Journal: Scientific Reports Scientific Reports
• what: Although patient-reported outcomes have been included in immunotherapy trials, this study provides a very frequent (every week) examination of symptom burden associated with immunotherapy compared to assessments done mostly at imaging visits (every 8-9 weeks).
• how: The study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.